m6A-centered Crosstalk Information
Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
| Crosstalk ID |
M6ACROT05481
|
[1] | |||
m6A modification
MIR93
MIR93
METTL3
Methylation
: m6A sites
Direct
Enhancement
Non-coding RNA
miR-93
DUSP2
lncRNA miRNA circRNA
|
|||||
| m6A Modification: | |||||
|---|---|---|---|---|---|
| m6A Regulator | Methyltransferase-like 3 (METTL3) | WRITER | |||
| m6A Target | microRNA 93 (MIR93) | ||||
| Epigenetic Regulation that have Cross-talk with This m6A Modification: | |||||
| Epigenetic Regulation Type | Non-coding RNA (ncRNA) | ||||
| Epigenetic Regulator | MicroRNA 93 (MIR93) | microRNA | View Details | ||
| Regulated Target | Dual specificity protein phosphatase 2 (DUSP2) | View Details | |||
| Crosstalk Relationship | m6A → ncRNA | Enhancement | |||
| Crosstalk Mechanism | m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA | ||||
| Crosstalk Summary | METTL3-mediated formation of EV microRNA 93 (MIR93), facilitated by m6A, is implicated in the aberrant cross-talk of epithelium-macrophages, indicating that this process is involved in the smoking-related emphysema. EV miR-93 was used as a novel risk biomarker for CS-induced emphysema. MiR-93 activated the JNK pathway by targeting Dual specificity protein phosphatase 2 (DUSP2), which elevated the levels of matrix metalloproteinase 9 (MMP9) and matrix metalloproteinase 12 (MMP12) and induced elastin degradation, leading to emphysema. | ||||
| Responsed Disease | Emphysema | ICD-11: CA21 | |||
| Pathway Response | MAPK signaling pathway | hsa04010 | |||
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
| CA21: Emphysema | 5 Compound(s) Regulating the Disease | Click to Show/Hide the Full List | ||
| Zemaira | Approved | [2] | ||
| Synonyms |
Alpha-1-antitrypsin
Click to Show/Hide
|
|||
| External Link | ||||
| Palovarotene | Phase 2 | [3] | ||
| Synonyms |
R-667; RG-667; Retinoid receptor agonist, Roche; Ro-3300074; Ro-330074
Click to Show/Hide
|
|||
| External Link | ||||
| Glassia | Approved | [4] | ||
| Synonyms |
Glassia (TN)
Click to Show/Hide
|
|||
| External Link | ||||
| Cilomilast | Discontinued in Phase 3 | [5] | ||
| Synonyms |
Ariflo; CIO; SB 207499; SB207499; Ariflo (TN); Cilomilast [USAN:INN]; SB-207499; Ariflo, SB-207499,Cilomilast; Cilomilast (JAN/USAN/INN); CIS-4-CYANO-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANECARBOXYLIC ACID; Cis-4-Cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexanecarboxylic acid; Cis-4-Cyano-4-(3-(cyclopentyloxy)-4-methoxyphenyl)cyclohexanecarboxylic acid; Cis-4-(3-(Cyclopentyloxy)-4-methoxyphenyl)-4-cyanocyclohexane-1-carboxylic acid; 4-cyano-4-(3-cyclopentoxy-4-methoxy-phenyl)-cyclohexane-1-carboxylic acid; 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane-1-carboxylic acid
Click to Show/Hide
|
|||
| External Link | ||||
| WIN-63759 | Terminated | [6] | ||
| Synonyms |
CHEMBL114992; SCHEMBL7305284; BDBM50036477; 2,6-Dichloro-3-(2-morpholin-4-yl-ethoxy)-benzoic acid 4-isopropyl-6-methoxy-1,1,3-trioxo-1,3-dihydro-1lambda*6*-benzo[d]isothiazol-2-ylmethyl ester(WIN63759); 2,6-Dichloro-3-(2-morpholin-4-yl-ethoxy)-benzoic acid 4-isopropyl-6-methoxy-1,1,3-trioxo-1,3-dihydro-1lambda*6*-benzo[d]isothiazol-2-ylmethyl ester
Click to Show/Hide
|
|||
| External Link | ||||
References
: m6A sites